Shares of this Pharma stock under the ‘micro-cap’ category hit its 10 percent upper circuit in Thursday’s trading session after Mr. Ashish Kacholia, one of the well-known ace investors based in India, bought a fresh stake in the company during the financial quarter ended March 2024.
With a market capitalization of Rs 197 crores, the stocks of Sanjivani Paranteral Limited started its trading session on Thursday hitting the 10 percent upper circuit at Rs 168.60, and, after some volatility, the company’s stock bounced back and settled at its circuit price. The scrip is inching towards its 52-week high price of Rs 188.35 apiece.
Such sharp movements in the company’s share price were witnessed after Mr. Ashish Kacholia, one of the well-known ace investors based in India, bought a fresh stake in Sanjivani Paranteral Limited.
According to the latest filings available, the ace investor subscribed to 3.70 lakh equity shares of Sanjivani Paranteral Limited equivalent to a 3.17 percent stake in the company. Currently, the holding value of his investment stands at Rs 6.20 crores.
During the recent financial quarters, the company’s basic business parameters, viz, its operating revenues as well as after-tax profits, showed some marginal movements in opposing directions.
The former, on one end, jumped from Rs 14 crores during Q2FY24 to Rs 14.96 crores during Q3FY24, and the latter, on the other end, dipped slightly from Rs 1.71 crores to Rs 1.65 crores.
As per the latest presentations, the company’s revenue mix reported a stellar performance pertaining to its ‘Injectables’ segment, shifting up from Rs 68.7 mn in Q2FY24 v/s Rs 95.8 mn of revenue in Q3FY24. On a contrasting note, the other segments, i.e., the ‘Oral’ & ‘Nutraceutical” segments, reported a dip in numbers.
Sanjivani Paranteral Limited is an India-based company engaged in the business of providing pharmaceutical products and services. With operations within as well as outside India, the company’s product portfolio includes anti-biotic, anti-diabetic, anti-fungal, calcium and vitamin, cardiovascular, and others.
Written by Amit Madnani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
